Conéctate
Conéctate
O Conectarse con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Regístrate
O Conectarse con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

EXAGEN INC.

(XGN)
  Reporte
Tiempo real estimado Cboe BZX  -  21:37 08/12/2022
2.560 USD   +11.30%
05/12Exagen Inc. Anuncia cambios ejecutivos
CI
17/11Exagen Inc. : BTIG mantiene su recomendación de compra
MM
15/11Exagen Inc. : El Canaccord Genuity continua con un recomendación de compra
MM
ResumenCotizacionesGráficosNoticiasRatingsAgendaEmpresaFinanzasConsensoRevisionesDerivadosFondos 
ResumenTodasRecomendaciones analistasOtros idiomasComunicadosPubls. oficialesNoticias del sector
Noticias en otros idiomas sobre EXAGEN INC.
05/12Exagen : Costs Associated with Exit/Disposal - Form 8-K
05/12Exagen Inc. : Costs Associated with Exit or Disposal Activities, Change in Directors or Pr..
05/12Exagen Inc. Announces Executive Changes
21/11EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
21/11EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
14/11Exagen Inc. : Results of Operations and Financial Condition, Non-Reliance on Previous Fina..
14/11Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $14.7M
14/11Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
14/11Exagen Inc. Reports Third Quarter 2022 Results
14/11Exagen Inc. Reports Third Quarter 2022 Results
14/11Exagen Inc. Increases Revenue Guidance for 2022
08/11Exagen Inc. to Participate in Fourth Quarter Investor Conferences
08/11Exagen Inc. to Participate in Fourth Quarter Investor Conferences
31/10Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
31/10Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
20/10Exagen Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financi..
17/10Exagen Names John Aballi Chief Executive
17/10Exagen Announces Appointment of John Aballi as CEO
17/10Exagen Inc. Appoints John Aballi as President
17/10Exagen Inc. Appoints John Aballi as CEO
04/10Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation ..
04/10Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation ..
04/10Exagen Inc. Appoints Andrew L. Concoff as Chief Innovation Officer
20/09Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
19/09Exagen Inc.(NasdaqGM:XGN) dropped from S&P Global BMI Index
15/09Exagen Inc. : Entry into a Material Definitive Agreement, Financial Statements and Exhibit..
01/09Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe C..
01/09Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe C..
25/08Octopus Energy unveils renewables fund backing UK's largest battery
24/08Octopus Energy buys stake in solar and battery business Exagen
04/08EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
04/08Exagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 3..
04/08Earnings Flash (XGN) EXAGEN Reports Q2 Revenue $9M
04/08Exagen : Reports Second Quarter 2022 Results - Form 8-K
04/08Exagen Inc. Reports Second Quarter 2022 Results
04/08Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients..
04/08Exagen Inc. Reports Second Quarter 2022 Results
04/08Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients..
04/08Exagen Inc. Initiates Study to Predict Rheumatoid Arthritis Drug Response in Patients w..
04/08Exagen Inc. Provides Revenue Guidance for the Year of 2022
25/07Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
21/07Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
21/07Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
05/07Exagen Inc. Releases Comparative Utility Study in Lupus Diagnostics Confirming AVISE(R)..
05/07Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE..
05/07Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE..
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 3000 Growth Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 2000 Dynamic Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 2000 Value Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell Small Cap Comp Value..
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 2000 Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 2500 Value Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 3000E Value Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 3000 Value Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 2000 Growth Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell Small Cap Comp Growt..
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 3000E Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 3000E Growth Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 3000 Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell Small Cap Completene..
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 2500 Growth Index
24/06Exagen Inc.(NasdaqGM:XGN) dropped from Russell 2500 Index
21/06Exagen Inc. : Submission of Matters to a Vote of Security Holders (form 8-K)
09/06Exagen Inc. Expands Coverage with MediNcrease
09/06Exagen Inc. Expands Coverage with MediNcrease
26/05Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
26/05Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
16/05Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
16/05Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
16/05Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
11/05EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
11/05Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
11/05Earnings Flash (XGN) EXAGEN Reports Q1 Revenue $10.4M, vs. Street Est of $10M
11/05Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te..
11/05Exagen Inc. Reports First Quarter 2022 Results
11/05Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te..
11/05Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te..
11/05Exagen Inc. Reports First Quarter 2022 Results
11/05Exagen Inc. Revises Revenue Guidance for the Full Year of 2022
01/05Exagen Announces Five-Week Campaign for Lupus Awareness Month
01/05Exagen Announces Five-Week Campaign for Lupus Awareness Month
28/04Exagen Inc. : Change in Directors or Principal Officers, Financial Statements and Exhibits..
25/04Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
20/04Exagen Inc. to Participate in Investor Summit Group's Q2 Conference
30/03Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
30/03Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
22/03EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
22/03Exagen Q4 Loss Widens, Revenue Flat; Full-Year Sales Guidance Trails Street View
22/03Exagen : Reports Fourth Quarter and Full Year 2021 Results - Form 8-K
22/03Earnings Flash (XGN) EXAGEN Posts Q4 Loss $-0.42, vs. Street Est of $-0.46
22/03Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $12.7M, vs. Street Est of $11.7M
22/03Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
22/03Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
22/03Exagen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
22/03Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
22/03Exagen Inc. Provides Revenue Guidance for the Full Year 2022
16/03Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board
16/03Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board
16/03Exagen Inc. Announces Board Appointments
09/03Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTec..